Actively Recruiting
The 1st Tumor CytokinoTherapy Database (TCTD-1)
Led by OncoCareClinic 308 Ltd · Updated on 2024-06-10
5000
Participants Needed
1
Research Sites
532 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Predicting the response of patients diagnosed with cancer to cytokinotherapy is essential to guide anti-tumor therapy complex strategy and subsequent adjuvant approach. Cytokinotherapy is a cost-effective, well-known available method of therapy for the patients with tumors. The objective response possibly correlates to the tumor's size, aggressiveness, age, and other primary factors. Multifactor analysis requires a large amount of data. Therefore, the investigators created the first database aimed to collect data concerning the patients with cancer and the clinical outcomes of cytokinogenetic therapy. The acquired data must be processed to detect the key factors effecting the outcomes. Cytokinotherapy is a universal therapeutic approach, although we lack information that would help to personalize it and reduce the rate of progression. The main goal is to find the relationship between initial patients' characteristics and effectiveness of cytokinotherapy for early risks detection. The predictive models that could be elaborated from the TCTD-1 analysis will complement knowledge of cytokinotherapy rationale. Predicting survival or other significant clinical criteria using TCTD-1 analysis results would greatly benefit the cancer patients' management.
CONDITIONS
Official Title
The 1st Tumor CytokinoTherapy Database (TCTD-1)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older with cancer
- Patients who have completed or are eligible to complete at least one course of cytogenetic therapy
- Patients applied to the OncoCare308 Clinic Ltd. hospital for cytogenetic therapy
- Patients who do not meet any of the exclusion criteria
You will not qualify if you...
- Patients under 18 or over 95 years old
- Patients with hematologic cancer or thyroid tumors
- Patients with contraindications for cytogenetic therapy
- Patients who die before starting therapy or before completing the first course
- Patients who do not sign informed consent for clinical observation in the hospital
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
OncocareClinic 308
Moscow, Russia
Actively Recruiting
Research Team
A
Artem L Kornilov, Master
CONTACT
T
Tamara V Filatova, Master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here